Literature DB >> 16705739

Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion.

Yi Lu1, Zhong Cai, Deborah L Galson, Guozhi Xiao, Yulin Liu, Diane E George, Mona F Melhem, Zhi Yao, Jian Zhang.   

Abstract

BACKGROUND: Monocyte chemotactic protein-1 (MCP-1) plays a key role in the recruitment and activation of monocytes during inflammation. Increased MCP-1 serum levels in patients with various cancers were correlated with advanced stage. Here, we evaluated the role of MCP-1 on prostate cancer (CaP) cell proliferation and invasion.
METHODS: Expression of MCP-1 in tissue specimens was analyzed by immunohistochemical staining. MCP-1 production was determined by ELISA in conditioned media collected from primary prostate epithelia (PrEC), LNCaP, C4-2B, PC3 cells, and hFOB. Cell proliferation and invasion were assayed by MTS assay and invasion chambers.
RESULTS: All CaP cells, as well as hFOB, produced high amount of MCP-1 compared to PrEC cells. MCP-1 expression levels were associated with advanced pathologic stage. MCP-1 induced proliferation and invasion of CaP cells and this was abolished partially either by CCR2 antagonist or PI3 Kinase inhibitor.
CONCLUSION: MCP-1 acts as a paracrine and autocrine factor for CaP growth and invasion. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16705739     DOI: 10.1002/pros.20464

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  106 in total

Review 1.  Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

2.  Anti-Inflammatory Agents for Cancer Therapy.

Authors:  Elizabeth R Rayburn; Scharri J Ezell; Ruiwen Zhang
Journal:  Mol Cell Pharmacol       Date:  2009

Review 3.  Chemokines in tumor angiogenesis and metastasis.

Authors:  Seema Singh; Anguraj Sadanandam; Rakesh K Singh
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

Review 4.  The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers.

Authors:  Élora Midavaine; Jérôme Côté; Philippe Sarret
Journal:  Cancer Metastasis Rev       Date:  2021-05-11       Impact factor: 9.264

5.  Monocyte chemotactic protein-1 and CC chemokine receptor 2 polymorphisms and prognosis of renal cell carcinoma.

Authors:  Guan-Xian Liu; Xin Zhang; Su Li; Richard D Koiiche; Jerry H Sindsceii; Haihan Song
Journal:  Tumour Biol       Date:  2013-05-09

6.  A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.

Authors:  Xin Li; Robert Loberg; Jinhui Liao; Chi Ying; Linda A Snyder; Kenneth J Pienta; Laurie K McCauley
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

7.  CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration.

Authors:  Robert D Loberg; Chi Ying; Matt Craig; Li Yan; Linda A Snyder; Kenneth J Pienta
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

Review 8.  CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-14       Impact factor: 7.638

9.  Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia.

Authors:  Kazutoshi Fujita; Charles M Ewing; Robert H Getzenberg; J Kellogg Parsons; William B Isaacs; Christian P Pavlovich
Journal:  Prostate       Date:  2010-04-01       Impact factor: 4.104

10.  Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.

Authors:  Kenneth J Pienta; Jean-Pascal Machiels; Dirk Schrijvers; Boris Alekseev; Mikhail Shkolnik; Simon J Crabb; Susan Li; Shobha Seetharam; Thomas A Puchalski; Chris Takimoto; Yusri Elsayed; Fitzroy Dawkins; Johann S de Bono
Journal:  Invest New Drugs       Date:  2012-08-21       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.